To assess the efficacy of Brentuximab Vedotin ± Bendamustine in the management of relapsed or refractory CD30-positive lymphomas, including classic Hodgkin lymphoma (cHL) and systemic anaplastic large cell lymphoma (sALCL). Methodology: An observational retrospective study was conducted at Aga Khan University Hospital, Pakistan, from January 2021 to June 2022. Eligible participants were aged 17 or older with CD30-positive disease (cHL or sALCL), having undergone at least one prior chemotherapy regimen and experiencing relapse or refractory disease. Treatment involved Brentuximab Vedotin ± Bendamustine, and patients were assessed using PET-CT scans. Results: Twenty-two patients received chemotherapy with Brentuximab Vedotin ± Bendamustine, comprising 19 with Hodgkin lymphoma and 3 with sALCL. Among them, 6 were in relapse, and 16 were refractory. At the end of treatment, 17 patients achieved complete response, 3 achieved partial response, and 1 had stable disease, yielding an overall response rate (ORR) of 90.9%. Nineteen patients survived, while 3 deceased. The median overall survival was 30 months. Commonly encountered side effects, including nausea, neutropenia, peripheral neuropathy, gastrointestinal disturbances, infusion reactions, and rash, were generally well tolerated. Conclusions: Brentuximab Vedotin ± Bendamustine demonstrates effectiveness and tolerability in patients with relapsed or refractory cHL and sALCL, even in heavily pretreated individuals. In middleincome countries like Pakistan, affordability and accessibility play pivotal roles in determining patient eligibility for this treatment regimen.